Low Sensitivity of International Classification of Diseases, Tenth Revision Coding for Culture-Confirmed Candidemia Cases in an Active Surveillance System: United States, 2019–2020

Abstract We evaluated healthcare facility use of International Classification of Diseases, Tenth Revision (ICD-10) codes for culture-confirmed candidemia cases detected by active public health surveillance during 2019–2020. Most cases (56%) did not receive a candidiasis code, suggesting that studies...

Full description

Saved in:
Bibliographic Details
Published inOpen forum infectious diseases Vol. 9; no. 9; p. ofac461
Main Authors Benedict, Kaitlin, Gold, Jeremy A W, Jenkins, Emily N, Roland, Jeremy, Barter, Devra, Czaja, Christopher A, Johnston, Helen, Clogher, Paula, Farley, Monica M, Revis, Andrew, Harrison, Lee H, Tourdot, Laura, Davis, Sarah Shrum, Phipps, Erin C, Felsen, Christina B, Tesini, Brenda L, Escutia, Gabriela, Pierce, Rebecca, Zhang, Alexia, Schaffner, William, Lyman, Meghan
Format Journal Article
LanguageEnglish
Published US Oxford University Press 01.09.2022
Subjects
Brief Report
public health surveillance
candidiasis
candidemia
sepsis
international classification of diseases
Online AccessGet full text

Cover

More Information
Summary:Abstract We evaluated healthcare facility use of International Classification of Diseases, Tenth Revision (ICD-10) codes for culture-confirmed candidemia cases detected by active public health surveillance during 2019–2020. Most cases (56%) did not receive a candidiasis code, suggesting that studies relying on ICD-10 codes likely underestimate disease burden.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Potential conflicts of interest. Christopher A. Czaja reports institutional support from Centers for Disease Control and Prevention cooperative agreements. Helen Johnston reports institutional support from the Centers for Disease Control and Prevention via the Emerging Infections Program cooperative agreement. Paula Clogher reports institutional support from the Centers for Disease Control and Prevention via the Emerging Infections Program cooperative agreement. Monica M. Farley reports institutional support from the Centers for Disease Control and Prevention via the Emerging Infections Program cooperative agreement, NIH/DMID grant to institution (unrelated to this project) and Centers for Disease Control and Prevention Foundation Grant to institution (unrelated to this project). Lee H. Harrison reports support for attending meetings and/or travel from GSK, Sanofi, Merck, Pfizer and Participation on a Data Safety Monitoring Board or Advisory Board (Merck). Sarah Shrum Davis reports institutional support from the Centers for Disease Control and Prevention via the Emerging Infections Program cooperative agreement. Erin C. Phipps reports institutional support from the Centers for Disease Control and Prevention. Brenda L. Tesini reports personal book writing honoraria from Merck. Rebecca Pierce reports institutional support from Centers for Disease Control and Prevention cooperative agreements. William Schaffner reports institutional support from the Centers for Disease Control and Prevention via the Emerging Infections Program cooperative agreement, consulting fees from VBI Vaccines outside the submitted work, and serves as Medical Director for National Foundation for Infectious Diseases outside the submitted work. All other authors report no conflicts of interest. All authors have completed the ICMJE Form for Disclosure of Potential Conflicts of Interest.
ISSN:2328-8957
2328-8957
DOI:10.1093/ofid/ofac461